Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00005818 · ClinicalTrials.gov registry record · Phase 1
SU5416 and Irinotecan in Treating Patients With Advanced Colorectal Cancer
A Phase 1 study, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 1
- Development phase
- 68
- Enrollment target
NCT00005818: Completed Phase 1 study, sponsored by National Cancer Institute (NCI).
NCT00005818 is a Phase 1 study that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 68 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00005818, a Phase 1 study, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 68 participants
- Enrollment target
Study Summary
Phase I/II trial to study the effectiveness of combining SU5416 and irinotecan in treating patients who have advanced colorectal cancer. SU5416 may stop the growth of colorectal cancer by stopping blood flow to the tumor. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die
Interventions
- OTHER laboratory biomarker analysis
- DRUG irinotecan hydrochloride
- DRUG semaxanib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 68 participants |
| Start Date | 2000-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00005818
The ClinicalTrials.gov registry entry for NCT00005818 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 68 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which laboratory biomarker analysis is the first listed.
NCT00005818 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00005818 about?
NCT00005818 is a clinical study titled "SU5416 and Irinotecan in Treating Patients With Advanced Colorectal Cancer". Phase I/II trial to study the effectiveness of combining SU5416 and irinotecan in treating patients who have advanced colorectal cancer. SU5416 may stop the growth of colorectal cancer by stopping blood flow to the tumor. Drugs used in chemotherapy use different ways to stop tumor cells from dividin...
What is the current status of trial NCT00005818?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 68 participants. The study started on 2000-03.
What interventions are being tested in trial NCT00005818?
The interventions under investigation include: laboratory biomarker analysis (OTHER), irinotecan hydrochloride (DRUG), semaxanib (DRUG).
Who is sponsoring clinical trial NCT00005818?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.